Fosun Pharma Shanghai announced on November 22, 2024, the progress of the privatization and merger of its controlling subsidiary Shanghai Henlius Biotech Co., Ltd. The privatization plan was approved by the board of directors on June 24, 2024, and August 23, 2024. It is planned that Fosun Pharma will acquire and cancel all shares of Henlius by cash and/or stock. After completion, Fosun Pharma will take over all the assets, liabilities, and business of Henlius. This transaction has obtained the record approval from the National Development and Reform Commission of China on November 21, 2024. However, the transaction still needs approvals from multiple government departments, including the Ministry of Commerce, the State Administration of Foreign Exchange, and the securities regulatory institutions in relevant jurisdictions. In addition, the...Show More

Fosun Pharma Shanghai announced on November 22, 2024, the progress of the privatization and merger of its controlling subsidiary Shanghai Henlius Biotech Co., Ltd. The privatization plan was approved by the board of directors on June 24, 2024, and August 23, 2024. It is planned that Fosun Pharma will acquire and cancel all shares of Henlius by cash and/or stock. After completion, Fosun Pharma will take over all the assets, liabilities, and business of Henlius. This transaction has obtained the record approval from the National Development and Reform Commission of China on November 21, 2024. However, the transaction still needs approvals from multiple government departments, including the Ministry of Commerce, the State Administration of Foreign Exchange, and the securities regulatory institutions in relevant jurisdictions. In addition, the shareholders' meeting of Henlius and the H-share category shareholders' meeting need to review and approve the relevant proposals, and their voluntary delisting application needs approval from The Stock Exchange of Hong Kong. Due to the remaining uncertainties in the transaction, Fosun Pharma reminds investors to pay attention to relevant risks. Whether the transaction can ultimately be completed depends on the decisions of multiple approvals and the shareholders' meetings.